LOGIN  |  REGISTER
C4 Therapeutics
Astria Therapeutics

Coherus BioSciences to Report First Quarter 2023 Financial Results on May 8, 2023

May 01, 2023 | Last Trade: US$1.18 0.02 1.72

REDWOOD CITY, Calif., May 01, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus“, Nasdaq: CHRS) today announced its first quarter 2023 financial results will be released after market close on Monday, May 8, 2023. Starting at 5:00 pm ET on May 8, 2023, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update.

A replay of the webcast will be available on http://investors.coherus.com following the conclusion of the live conference call.

Conference Call Information

When: Monday, May 8th, 2023, starting at 5:00 p.m. Eastern Time
To access the conference call, please pre-register through the following link to receive dial-in information and a personal PIN to access the live call: https://register.vevent.com/register/BI12e6d284dae8440e91891f2cef4f2097

Webcast: https://edge.media-server.com/mmc/p/ugoyrevj

The press release with the first quarter financial results and related materials will be available at https://investors.coherus.com prior to the start of the conference call.

A live and archived webcast will be available on the “Investors” section of the Coherus website at http://investors.coherus.com.

Please dial-in 15 minutes early to ensure a timely connection to the call.

Coherus Contact Information:
Marek Ciszewski, SVP Investor Relations
This email address is being protected from spambots. You need JavaScript enabled to view it.

Astria Therapeutics

Stock Quote

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page